《美股》HIV药大厂吉利德科学(GILD.US)次季盈利胜预期 上调全年盈测 盘前升近3%
HIV预防及治疗药巨擘吉利德科学(Gilead Sciences)(GILD.US)公布2025年第二季财报,总收入按年增2%至71亿美元,符市场预期,主要受HIV药物Biktarvy、Descovy、Trodelvy及Livdelzi销售增长推动,惟慢性丙型肝炎药物及Veklury销售下跌抵销部分增幅。次季剔除Veklury的产品销售按年增4%至69亿美元,其中Biktarvy销售额升9%至35亿美元。总HIV相关产品销售按年升7%至51亿美元。
公司录得每股摊薄盈利1.56美元,较去年同期的1.29美元增长,主要受证券未实现收益及产品销售增加带动,惟部分被1,900万美元的研发资产减值及研发费用上升抵销。非公认会计准则每股摊薄盈利为2.01美元,与去年同期持平,并胜市场预期的每股1.97美元。
截至2025年6月底,公司持有现金、现金等价物及有价证券71亿美元,第二季经营现金流为8.27亿美元。公司于季内支付股息9.94亿美元,并回购5.27亿美元普通股。
公司预期全年收入及盈利指引上调,料全年经调整每股盈利介乎7.95至8.25美元,高于原先介乎7.7至8.1美元,市场料每股8.01美元;亦上调产品销售预测至介乎283亿至287亿美元,高于原先介乎282亿至286亿美元,市场料287亿美元,并持续推进核心治疗领域的创新及增长。
该股盘前交易时段升2.9%,报113.47美元。~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.